Clinical Trials Browser

Phase 4 × OTHER × secukinumab × Clear all

NCT06833112 2025-02-18

Interleukin-17 (IL-17) Inhibitor in Combination With Tumor Necrosis Factor α (TNFα )Inhibitor for the Treatment of Ankylosing Spondylitis

Phase 4 Not yet recruiting

Spondylitis, Ankylosing

NCT04571567 2022-04-11

A Study to Evaluate the Efficacy and Safety of Secukinumab in Adult Patients With Skin Types IV-VI With Moderate to Severe Plaque Psoriasis

Phase 4 Completed

Lymphoma, Follicular, Psoriasis